From: The extension of total gain (TG) statistic in survival models: properties and applications
 | Est. TG STD (t) at 3 time points |  |  |  | Est. \(R_{\textit {BS}}^{2}(t)\) at 3 time points | ||||
---|---|---|---|---|---|---|---|---|---|
Study | \(\widehat {{TG}}_{\textit {STD}}{(T}_{1}{)}\) | \( \widehat {{TG}}_{\textit {STD}}{(T}_{2}{)}\) | \(\widehat {{TG} }_{\textit {STD}}{(T}_{3}{)}\) | \(\widehat {{R}}_{\textit {PM}}^{2}\) | \( \widehat {{R}}_{D}^{2}\) | \(\widehat {{\rho }}_{W}^{2}\) | \( \widehat {{R}}_{\textit {BS}}^{2}{(T}_{1}{)}\) | \(\widehat {{R }}_{\textit {BS}}^{2}{(T}_{2}{)}\) | \(\widehat {{R}}_{\textit {BS}}^{2} {(T}_{3}{)}\) |
Breast | 0.32 | 0.33 | 0.35 | 0.27 | 0.28 | 0.36 | 0.12 | 0.16 | 0.20 |
cancer | (0.27-0.37) | (0.28-0.38) | (0.30-0.40) | (0.21-0.35) | (0.21-0.35) | (0.29-0.47) | (0.07-0.18) | (0.10-0.21) | (0.14-0.25) |
Lymphoma | 0.28 | 0.31 | 0.36 | 0.23 | 0.23 | 0.32 | 0.16 | 0.22 | 0.24 |
 | (0.16-0.40) | (0.18-0.44) | (0.21-0.50) | (0.11-0.42) | (0.11-0.40) | (0.15-0.53) | (0.02-0.24) | (0.05-0.34) | (0.07-0.38) |
PBC | 0.58 | 0.62 | 0.56 | 0.56 | 0.65 | 0.60 | 0.38 | 0.47 | 0.47 |
 | (0.52-0.65) | (0.54-0.70) | (0.50-0.62) | (0.48-0.65) | (0.55-0.74) | (0.53-0.68) | (0.19-0.52) | (0.38-0.58) | (0.34-0.57) |
Renal | 0.34 | 0.37 | 0.41 | 0.27 | 0.26 | 0.33 | 0.24 | 0.27 | 0.19 |
cancer | (0.28-0.40) | (0.31-0.42) | (0.36-0.46) | (0.21-0.36) | (0.20-0.33) | (0.27-0.42) | (0.16-0.31) | (0.21-0.34) | (0.11-0.26) |
Prostate | 0.22 | 0.24 | 0.26 | 0.13 | 0.13 | 0.18 | 0.06 | 0.11 | 0.10 |
cancer | (0.17-0.27) | (0.19-0.29) | (0.21-0.32) | (0.09-0.20) | (0.09-0.21) | (0.13-0.27) | (0.02-0.10) | (0.06-0.15) | (0.05-0.14) |